{"disease":{"id":"duchenne-muscular-dystrophy","name":"Duchenne muscular dystrophy","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"golodirsen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyondys 53","generic_name":"GOLODIRSEN","company_name":"Sarepta","drug_phase":"marketed","molecular_target":"exon 53 of dystrophin pre-mRNA","drug_class":"Antisense Oligonucleotide [EPC]","quality_score":66,"revenue":"400","mechanism":"Vyondys 53 works by binding to specific RNA sequences to prevent the production of a faulty dystrophin protein."},{"drug_id":"casimersen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amondys 45","generic_name":"CASIMERSEN","company_name":"Sarepta","drug_phase":"marketed","molecular_target":"exon 53 of dystrophin pre-mRNA","drug_class":"Antisense Oligonucleotide [EPC]","quality_score":65,"revenue":"400","mechanism":"Amondys 45 works by binding to specific RNA sequences to prevent the production of a faulty protein that causes Duchenne muscular dystrophy."},{"drug_id":"eteplirsen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exondys 51","generic_name":"ETEPLIRSEN","company_name":"Sarepta","drug_phase":"marketed","molecular_target":"exon 51 of dystrophin pre-mRNA","drug_class":"Antisense Oligonucleotide [EPC]","quality_score":59,"revenue":"300","mechanism":"Exondys 51 binds to specific RNA sequences to prevent the skipping of exon 51 during dystrophin mRNA splicing."},{"drug_id":"vamorolone","indication_name":"Duchenne muscular dystrophy (DMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Agamree","generic_name":"VAMOROLONE","company_name":"Catalyst Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Agamree works by inhibiting the activity of pro-inflammatory enzymes, reducing muscle damage and inflammation in Duchenne muscular dystrophy."},{"drug_id":"ataluren","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Translarna","generic_name":"ATALUREN","company_name":"PTC Therapeutics International Limited","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH)","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"viltolarsen","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viltepso","generic_name":"VILTOLARSEN","company_name":"Nippon Shinyaku","drug_phase":"marketed","molecular_target":"exon 53 of dystrophin pre-mRNA","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Viltepso works by binding to exon 53 of dystrophin pre-mRNA, allowing for the production of a partially functional dystrophin protein."},{"drug_id":"deflazacort","indication_name":"Duchenne muscular dystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emflaza","generic_name":"DEFLAZACORT","company_name":"Ptc Therap","drug_phase":"marketed","molecular_target":"","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":"Emflaza works by mimicking the effects of cortisol, a natural hormone produced by the body, to reduce inflammation and suppress the immune system."},{"drug_id":"givinostat","indication_name":"Duchenne muscular dystrophy (DMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Duvyzat","generic_name":"GIVINOSTAT","company_name":"Italfarmaco Spa","drug_phase":"marketed","molecular_target":"","drug_class":"Histone Deacetylase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Duvyzat works by blocking enzymes that compact chromatin and silence genes."}],"pipeline":[{"drug_id":"fordadistrogene-movaparvovec","indication_name":"Duchenne Muscular Dystrophy (early-stage)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"fordadistrogene movaparvovec","generic_name":"fordadistrogene-movaparvovec","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Dystrophin gene (DMD); AAV9 receptor (AAVR)","drug_class":"Gene therapy; In vivo gene delivery","quality_score":null,"revenue":null,"mechanism":"Fordadistrogene movaparvovec delivers a functional dystrophin gene via AAV9 vector to restore muscle protein expression in Duchenne muscular dystrophy."}],"offLabel":[],"totalMarketed":8,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04972604","title":"CureDuchenne Link®: A Resource for Research","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"CureDuchenne","has_results":false},{"nct_id":"NCT04012671","title":"A Registered Cohort Study on Duchenne Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Ning Wang, MD., PhD.","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT03443115","title":"Duchenne Muscular Dystrophy Heart Study","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Hôpital Cochin","has_results":false},{"nct_id":"NCT04120168","title":"Study Determining the Frequency of Duchenne Muscular Dystrophy and Late-onset Pompe Disease","phase":"","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Turkish Society of Pediatric Gastroenterology, Hepatology and Nutrition","has_results":false},{"nct_id":"NCT01484678","title":"Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":550,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT06270719","title":"An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07467187","title":"Invasive Home Ventilation in Denmark","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05967351","title":"A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04583917","title":"Brain Involvement in Dystrophinopathies Part 1","phase":"","overall_status":"COMPLETED","enrollment_count":377,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT04668716","title":"Brain Involvement in Dystrophinopathies Part 2","phase":"","overall_status":"COMPLETED","enrollment_count":339,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":false},{"nct_id":"NCT03760029","title":"A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy","phase":"NA","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06606340","title":"A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06711692","title":"The U.K. NorthStar Clinical Network","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT01247207","title":"Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"PTC Therapeutics","has_results":false},{"nct_id":"NCT01753804","title":"A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.","phase":"","overall_status":"TERMINATED","enrollment_count":269,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":false},{"nct_id":"NCT06366815","title":"phenotypeS in Non Ambulant Duchenne Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02500381","title":"Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03882827","title":"Natural History of Duchenne Muscular Dystrophy","phase":"","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Genethon","has_results":false},{"nct_id":"NCT03513367","title":"The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.","phase":"","overall_status":"UNKNOWN","enrollment_count":210,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06579859","title":"Development of a Registry to Assess Natural History in Duchenne Muscular Dystrophy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02851797","title":"Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":179,"lead_sponsor_name":"Italfarmaco","has_results":true},{"nct_id":"NCT00592553","title":"Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT00847379","title":"Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":173,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT03532542","title":"An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":171,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03039686","title":"Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03603288","title":"Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":161,"lead_sponsor_name":"Santhera Pharmaceuticals","has_results":false},{"nct_id":"NCT05712447","title":"Duchenne Muscular Dystrophy Video Assessment Registry","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"The Emmes Company, LLC","has_results":false},{"nct_id":"NCT05881408","title":"A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":148,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03917719","title":"An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":130,"lead_sponsor_name":"Catabasis Pharmaceuticals","has_results":false},{"nct_id":"NCT05096221","title":"A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT02310763","title":"A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":121,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03439670","title":"A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"ReveraGen BioPharma, Inc.","has_results":true},{"nct_id":"NCT03836300","title":"Parent and Infant Inter(X)Action Intervention (PIXI)","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":120,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04281485","title":"Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":114,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02255552","title":"Study of Eteplirsen in DMD Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Sarepta Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06839469","title":"Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT07092540","title":"The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":105,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT05715957","title":"Follow-up Study on Female Carriers With DMD Gene Variants","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":103,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT02994030","title":"Biomarker for Duchenne Muscular Dystrophy","phase":"","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT07129954","title":"Fear of Falling in Muscular Dystrophy","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT04371666","title":"Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":98,"lead_sponsor_name":"Kyntra Bio","has_results":true},{"nct_id":"NCT05575648","title":"Dual Task in Duchenne Muscular Dystrophy","phase":"NA","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT01557400","title":"Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT03354039","title":"Tamoxifen in Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT05549999","title":"Cultural Adaptation, Validity, and Reliability of the Turkish Version of North Star Ambulatory Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Hacettepe University","has_results":false},{"nct_id":"NCT03372655","title":"Prognostic Factors Affecting Duchenne Muscular Dystrophy","phase":"","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06565208","title":"First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"Satellos Bioscience, Inc.","has_results":false},{"nct_id":"NCT04060199","title":"Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"NS Pharma, Inc.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}